Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin and Rifaximin for AIEC Eradication in Crohn's Disease
NCT02620007Phase 2Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2015
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ciprofloxacin, rifaximin in Crohn's disease, sponsored by Assistance publique - Hôpitaux de Paris. Started Dec 2015; status: terminated.
02
Drugs
ciprofloxacinrifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02620007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620007.